xamoterol has been researched along with neuropeptide y in 1 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (neuropeptide y) | Trials (neuropeptide y) | Recent Studies (post-2010) (neuropeptide y) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 10,663 | 152 | 2,269 |
| Protein | Taxonomy | xamoterol (IC50) | neuropeptide y (IC50) |
|---|---|---|---|
| Neuropeptide Y receptor type 1 | Homo sapiens (human) | 0.0014 | |
| Neuropeptide Y receptor type 2 | Homo sapiens (human) | 0.0003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andréasson, K; Erhardt, L; Eriksson, SV; Hall, C; Hjemdahl, P; Kahan, T; Persson, H; Tidgren, B | 1 |
1 trial(s) available for xamoterol and neuropeptide y
| Article | Year |
|---|---|
Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Chi-Square Distribution; Dopamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Echocardiography, Doppler; Epinephrine; Female; Follow-Up Studies; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Myocardial Infarction; Neuropeptide Y; Norepinephrine; Probability; Proportional Hazards Models; Prospective Studies; Survival Rate; Treatment Outcome; Xamoterol | 2002 |